New antiangiogenic agents for renal cell carcinoma: Interferon alfa and thalidomide
β Scribed by Ronald M. Bukowski
- Book ID
- 107546275
- Publisher
- Current Science Inc.
- Year
- 2004
- Tongue
- English
- Weight
- 92 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1523-3790
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. The purpose of the study was to evaluate the efficacy and safety of a boneβtargeted regimen consisting of zoledronate, thalidomide, and interferonβΞ³ in patients with renal cell carcinoma and bone metastases. ## METHODS. Eligible patients had radiographic evidence of bo
A 57-year-old woman developed pulmonary sarcoidosis during therapy with interferon /3 for advanced renal cell carcinoma metastatic to mediastinal lymph nodes. The possible role of interferon /3 in the pathogenesis of sarcoidosis in this patient is discussed.
Thirty-three patients with measurable metastatic renal cell carcinoma were entered into 2 consecutive phase II protocols using interferon alfa-2a. In protocol I, 20 patients were treated with interferon alfa-2a at a dose of 36 x I06 IU i.m. t.i.w. Vinblastine was also given t o 18 of these patients